The LIBERATE study: Hormone replacement therapy with tibolone increases the risk of recurrence and metastases in breast cancer patients;LIBERATE-Studie: Hormonersatztherapie mit Tibolon erhöht das Rezidivrisiko bei Mammakarzinompatientinnen

Geburtshilfe und Frauenheilkunde

Volumn 69, Issue 3, 2009, Pages 199-201

  Untch, M ^a   Beckmann, M W ^b   Emons, G ^c   Thomssen, C ^d   Kimmig, R ^e  

^a HELIOS KLINIKUM BERLIN BUCH   (Germany)

^b UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^c UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^d MARTIN LUTHER UNIVERSITÄT HALLE WITTENBERG   (Germany)

^e UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

Adjuvant therapy; Bone loss; Breast cancer; Climacteric symptoms; Hormone replacement therapy; Osteoporosis; Tibolone

Indexed keywords

AROMATASE INHIBITOR; ESTROGEN RECEPTOR; PLACEBO; TAMOXIFEN; TIBOLONE;

BONE DENSITY; BREAST CANCER; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER RECURRENCE; CARDIOVASCULAR RISK; CLINICAL TRIAL; FRACTURE; HUMAN; METASTASIS; OSTEOPOROSIS; RECURRENCE RISK; REVIEW; TREATMENT DURATION; VASOMOTOR REFLEX;

EID: 77149131572     PISSN: 00165751     EISSN: 14388804     Source Type: Journal    
DOI: 10.1055/s-0029-1185524     Document Type: Review

References (6)

1. Kenemans P, Bundred NJ, Foidart J-M et al., on behalf of the LIBERATE Study Group. Safety and efficacy of tibolone in breast-cancer patients with vasomotor symptoms: a double-blind, randomised, non-inferiority trial. Lancet Oncol 2009; 10: 135-146
2. Cummings SR, Ettinger B, Delmas PD et al., for the LIFT Trial Investigators. The effect of tibolone in older postmenopausal women. N Engl J Med 2008; 359: 697-708
3. El-Hajj Fuleihan G. Tibolone and the promise of ideal hormone-replacement therapy. N Engl J Med 2008; 359: 753-755
4. Bundred NJ, Kenemans P, Beckmann MW et al. Effect of tibolone on breast cancer recurrence: LIBERATE trial bone sub-study. Breast Cancer Res Treatm 2009; 69 (Suppl 2); January 15, 2009
5. Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. The Lancet 2003; 362: 419-427
6. Holmberg L, Anderson H, for the HABITS steering and data monitoring committees. HABITS (hormonal replacement therapy after breast cancer - is it safe?), a randomised comparison: trial stopped. The Lancet 2004; 363: 453-455 (Pubitemid 38210063)